Groupe Francophone des Myélodysplasies

Recent papers from Groupe Francophone des Myélodysplasies

1. Enhanced Recovery After Liver Surgery: Does Compliance Impact Survival?Annals of Surgical Oncology · 2026
2. Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?Leukemia · 2026
3. Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availabilityBlood Advances · 2025
4. Street albedo distribution's impacts on air temperature and outdoor thermal sensation during heat and cold wavesUrban Climate · 2025
5. Efficacy and safety of luspatercept with or without erythropoiesis‐stimulating agent in patients with myelodysplastic neoplasms with ring sideroblasts: A multicentre real‐life study by the GFMBritish Journal of Haematology · 2025
6. Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLHemaSphere · 2025
7. FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des MyélodysplasiesHaematologica · 2024
8. Optimal results through enhanced recovery: Achieving textbook outcomes with high compliance in elective liver surgeryWorld Journal of Surgery · 2024
9. The genus Siderus (Lepidoptera: Lycaenidae) in French Guiana: four newly discovered species and conspicuous male genitalia polymorphismZootaxa · 2024
10. Eltrombopag in Chronic Myelomonocytic Leukemia With Severe Thrombocytopenia. A Gfm Study2024
11. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trialLeukemia · 2023
12. Two new Thereus species from Peru, with notes on ecological niche partitioning (Lepidoptera: Lycaenidae: Theclinae)Zootaxa · 2023
13. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Journal of Clinical Oncology · 2023
14. Validated French translation of the ESIT-SQ standardized tinnitus screening questionnaireEuropean Annals of Otorhinolaryngology Head and Neck Diseases · 2023
15. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkJournal of Clinical Oncology · 2022
16. The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high‐risk clonal cytopenia of unknown significanceGenes Chromosomes and Cancer · 2022
17. Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratoryBMC Cancer · 2022
18. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCOLeukemia · 2022
19. Probiotics/Synbiotics to Reduce Infectious Complications after Colorectal Surgery: A Systematic Review and Meta-Analysis of Randomised Controlled TrialsNutrients · 2022
20. A randomised phaseIIstudy of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) inhigher‐Risk MDSor low blastAML:GFM's “pick a winner” trial, with the impact of somatic mutationsBritish Journal of Haematology · 2022